Bio-Techne Schedules Investor Presentations at Upcoming Conferences

Bio-Techne will present at three investor conferences: the Wells Fargo Healthcare Conference, the Baird Global Healthcare Conference, and the Morgan Stanley Global Healthcare Conference. The presentations will take place on September 3, 9, and 10, respectively, and can be accessed via the company's Investor Relations website. Bio-Techne is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostics.

OmniAb, Inc. (OABI), a biopharmaceutical company focused on therapeutic antibody discovery, has been actively engaging in strategic moves to bolster its financial position and scientific advancements. In recent months, the company has announced several key developments that reflect its commitment to innovation and growth.

Private Placement and Board Changes

On August 25, 2025, OmniAb announced a private placement to raise approximately $30 million through the sale of 21,254,106 shares of common stock. The shares were priced at $1.40 per share, with officer and director participants paying $1.85 per share. The proceeds from this placement will be used for general corporate purposes, and OmniAb will file a registration statement with the SEC for the resale of these shares [1].

Additionally, the company made strategic appointments to its Board of Directors. Dr. Philip J. Gotwals, a biopharmaceutical veteran, and Steve Crouse, a senior executive from Bio-Techne, joined the board. These appointments aim to enhance the company's strategic direction and operational capabilities [2].

Financial Performance and Guidance

OmniAb's financial performance has been marked by both challenges and milestones. In Q2 2025, the company reported a net loss of $15.9 million ($0.15 per share) on revenue of $3.9 million. Despite the loss, OmniAb achieved significant business milestones, including reaching 100 active partners and 381 active programs, with 32 OmniAb-derived programs in clinical development or commercialization [3].

The company maintains its 2025 revenue guidance of $20-25 million and expects operating expenses of $85-90 million. Notable highlights include the launch of the xPloration® Partner Access Program and the initiation of Phase 3 trials for IMVT-1402 by partner Immunovant [3].

Innovative Platform and Partnerships

OmniAb showcased its innovative xPloration platform at the 21st Annual PEGS Boston Summit. The platform leverages machine learning and AI to enhance antibody discovery and development capabilities. The xPloration instrument features a laser-based "touchless" cell recovery process and can process millions of single B-cells within hours, significantly increasing the speed and efficiency of antibody discovery [4].

The company has also entered into six new license agreements in Q2 2025, expanding its partnership network and reinforcing its position in the biopharmaceutical industry [3].

Investor Conferences and Upcoming Events

OmniAb is actively engaging with investors through various conferences and events. The company has announced its participation in five upcoming investor conferences, including the H.C. Wainwright 1st Annual Royalty Company Virtual Conference and the RBC Capital Markets Global Healthcare Conference [5].

Conclusion

OmniAb's strategic moves and financial performance reflect its commitment to innovation and growth in the biopharmaceutical sector. The company's focus on cutting-edge technology and strategic partnerships positions it well for future success. As the company continues to navigate its financial challenges, investors will closely monitor its progress and the impact of its strategic initiatives on its financial performance.

References

[1] https://www.stocktitan.net/news/OABI/
[2] https://www.stocktitan.net/news/OABI/
[3] https://www.stocktitan.net/news/OABI/
[4] https://www.stocktitan.net/news/OABI/
[5] https://www.stocktitan.net/news/OABI/